AMG 623

DRUG2 trials

Sponsors

Amgen

Conditions

Systemic Lupus Erythematosus

Phase 1

A Study to Examine the Safety, Pharmacokinetics and Pharmacodynamics of AMG 623 in Subjects With Systemic Lupus Erythematosus

CompletedNCT02411136

AmgenSystemic Lupus Erythematosus

Start: 2005-05-31End: 2007-10-31Updated: 2015-04-08

A Study to Examine the Safety, Pharmacokinetics and Pharmacodynamics of Single Dose of AMG 623 in Subjects With Systemic Lupus Erythematosus

CompletedNCT02443506

AmgenSystemic Lupus Erythematosus

Start: 2004-10-31End: 2007-06-30Updated: 2015-05-14

Related Papers

Treatment of systemic lupus erythematosus patients with the BAFF antagonist "peptibody" blisibimod (AMG 623/A-623): results from randomized, double-blind phase 1a and phase 1b trials.

2015-08-2044 citations